Charles Bankhead is a staff writer for MedPage Today, a leading source of medical news. With a focus on healthcare and medicine, Charles covers a wide range of topics including emerging treatments, clinical challenges, FDA approvals, and advancements in various medical fields. His work has also been featured in Knowledia.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Charles Bankhead's focus is primarily on medical research, clinical trials, FDA approvals, and scientific developments in healthcare and pharmaceuticals. His coverage includes citing data from various studies and press releases.
If you are reaching out to Charles, consider providing insights or commentary based on recent medical research findings or clinical trial outcomes. Expert opinions related to FDA approvals, drug therapies, or challenges in specific areas of healthcare could be well-received by him.
Since his geographic focus is not specified but his topics are broad and universal, pitches can come from experts across the globe who have valuable insights into these areas of medical research and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Charles Bankhead
— News, features, and commentary about cancer-related issues The U.S. Attorney's Office filed a civil lawsuit against a Montana oncologist
By: Charles Bankhead
— Responses to pirtobrutinib observed in patients with previously treated disease
By: Charles Bankhead
— No difference in overall survival with versus without bolus, less toxicity without
By: Charles Bankhead
— Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy
By: Charles Bankhead
— Absolute improvement of almost 30%, doubling of duration of response with savolitinib
By: Charles Bankhead
— Incidence almost identical to that with standard cancer treatment in randomized trials
By: Charles Bankhead
— News, features, and commentary about cancer-related issues Rates of cancer diagnosis opens in a new tab or window still have not returned
— Designed for certain models, software can customize audio parameters
By: Charles Bankhead
— Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223
By: Charles Bankhead
— Adding lenvatinib, pembrolizumab to TACE significantly improved PFS, numerically improved OS
(833) 317-6278 
